Read the interview given by Drs. Grieco and Achee to the University of Notre Dame’s student run paper, The Observer, on the preparations for the launch of the Kenya trial this summer. They also touch on the next steps for the spatial repellents class to receive a public health policy recommendation which will allow small companies a better opportunity to pursue putting their spatial repellents on consumer and public health markets.
This project is made possible thanks to Unitaid funding and support. Unitaid is a global health agency engaged in finding innovative solutions to prevent, diagnose, and treat diseases more quickly, effectively, and for affordable prices, in low- and middle-income countries. Unitaid’s work includes funding initiatives to address major diseases such as HIV/AIDS, malaria, and tuberculosis, as well as HIV co-infections and co-morbidities such as cervical cancer and hepatitis C, and cross-cutting areas, such as fever management. Unitaid is now applying its expertise to address challenges in advancing new therapies and diagnostics for the COVID-19 pandemic, serving as a key member of the Access to COVID Tools Accelerator. Unitaid is hosted by the World Health Organization.